Diabetes mellitus may affect the long-term survival of hepatitis B virus-related hepatocellular carcinoma patients after liver transplantation

Table 3 Univariate analysis of overall 1-, 3- and 5-year survival rates post-liver transplantation between patients with diabetes mellitus and without diabetes mellitus

Variables	DM, %			Non-DM, %			P value
	1 yr	3 yr	5 yr	1 yr	3 yr	5 yr
Sex
Male	80	74	72	84	77	75	0.140
Female	76	62	62	90	88	86	0.016
Age, yr
≤ 50	80	73	73	80	74	71	0.970
> 50	79	73	71	88	83	80	0.002
Tumor size, in cm
≤ 3	83	79	79	90	86	83	0.047
3-5	86	79	74	87	79	77	0.689
5-7	66	49	43	71	65	63	0.171
> 7	36	30	30	63	49	48	0.055
Number of tumor nodules
Single	85	82	79	90	84	82	0.325
2-3	73	68	68	86	81	79	0.007
≥ 4	76	62	60	72	64	61	0.961
Venous invasion
Absent	85	80	79	88	84	82	0.113
Present	45	28	25	63	47	42	0.033
Lymph node invasion
Absent	80	74	72	85	79	76	0.032
Present	73	64	64	78	70	66	0.979
Capsular invasion
Absent	80	74	72	85	79	77	0.050
Present	75	61	61	79	72	70	0.554
Edmondson
1	91	91	91	100	100	100	0.134
2	82	77	75	87	81	78	0.124
3 + 4 + 5	74	66	64	79	73	71	0.229
Serum AFP level, in ng/mL
< 200	85	81	79	88	83	82	0.161
200-400	64	64	64	78	68	66	0.502
400-1000	71	51	42	82	72	66	0.189
1000-2000	68	41	41	73	61	55	0.454
> 2000	34	26	26	62	56	51	0.052
MELD score
< 10	79	68	68	84	77	74	0.101
10-15	78	70	70	84	78	76	0.197
> 15	82	80	75	85	80	78	0.423
Child-Pugh class
A (5-6)	83	78	78	85	79	76	0.792
B (7-9)	75	67	63	83	78	75	0.018
C (≥ 9)	79	74	72	82	77	75	0.479
Fasting blood glucose, in mmol/L
≤ 7	77	73	71	85	79	76	0.145
> 7	80	73	71	80	73	67	0.955
BMI, in kg/m2
< 18.5	68	62	62	81	79	76	0.156
18.5-24	77	72	70	84	78	76	0.048
24-28	86	78	76	85	79	76	0.951
> 28	81	72	72	85	80	74	0.656
ALP
≤ 112	83	78	76	87	81	78	0.281
> 112	74	66	65	80	74	72	0.102
GGT
≤ 54	87	86	85	92	88	85	0.559
> 54	75	66	63	79	72	69	0.104
ALT, in IU/L
≤ 40	86	81	80	89	85	83	0.339
40-80	73	68	65	83	77	74	0.017
> 80	77	68	66	75	68	64	0.633
AST, in IU/L
≤ 40	88	82	80	91	86	84	0.307
40-80	76	71	70	85	78	76	0.038
> 80	74	67	64	74	68	64	0.872
TC, in mmol/L
≤ 1.7	79	72	71	85	79	77	0.021
> 1.7	82	79	76	79	71	64	0.473
CH, in mmol/L
≤ 3.88	81	75	73	85	80	77	0.151
3.88-5.2	74	69	67	86	78	75	0.058
> 5.2	83	71	71	77	71	68	0.737
Pre-LT antitumor therapy
No	77	73	71	85	79	76	0.020
local therapy	83	71	71	79	73	71	0.910
Resection	92	80	72	88	84	80	0.809
HBeAg
Negative	79	73	71	85	78	76	0.055
Positive	82	75	73	83	79	76	0.446
HBV-DNA, in × 103 U/mL
< 1	80	73	71	85	79	78	0.072
> 1	77	73	72	84	77	74	0.236
Post-LT HBsAg reinfection
Negative	79	73	72	84	79	76	0.045
Positive	80	70	60	87	73	69	0.678

BMI: Body mass index; DM: Diabetes mellitus; ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GGT: Gamma-glutamyl transpeptidase; TG: Triglyceride; CH: Cholesterol; HBV: Hepatitis B virus; HBeAg: Hepatitis B e antigen; LT: Liver transplantation.